The Innate Immunity group has been active since 2009 and is focussed on the study of Innate Immunity in health and disease. It is located in the IGTP, Can Ruti Campus, and it is part of the CIBERehd Consortium of the Spanish Government (ISCIII) and the AGAUR Research Quality Group 2017-SGR-490. We are conducting research on three important aspects of human pathology: liver disease, atherosclerosis and bacterial infection.

Our aim is to define the role of Innate Immunity proteins as prognostic or diagnostic biomarkers of disease. We also aim at generating knowledge for the development of new pharmacological agents that modulate Innate Immune responses. In this context, our interests are at present mostly centred on the role of macrophage protein CD5L in the control of immune homeostasis and inflammatory disease.

See Publications

Research lines

Role of Innate Immunity in liver disease

Our main objective is to study microenvironment interactions in the setting of liver disease. Our functional studies are focussed on the intercommunication between two key liver cell types, macrophages and hepatic stellate cells, with hepatocytes. With a more clinically oriented goal, we are exploring the potential of several Innate Immunity proteins as biomarkers for the improvement of patient management. Both approaches will lead to a better understanding of the complex mechanisms underlying liver disease.

This work has been funded by grants from ISCIII- ERDF (FIS PI13/1906, Miguel Servet CPII/14/0021, Juan de la Cierva, FJCI-2014-20505), and La Marató de TV3 Foundation (MTV3-20133610).

Role of CD5L and CD36 in the physiology of macrophages in atherosclerosis

Under persistent hyperlipidemic conditions, a series of changes in the vessel wall may lead to atherosclerosis, a chronic inflammatory condition in which macrophages play a key role. Complications of atherosclerosis such as plaque rupture and thrombosis are the most common causes of death in Western societies. Our purpose is to determine the contribution of CD5L and its cellular receptor CD36 to key events of macrophage physiology in the context of atherosclerosis.

This work has been funded by grants from La Marató de TV3 Foundation (MTV3 080932), and the European Foundation for the Study of Diabetes (EFSD).

Role of CD5L in bacterial infection

The Innate Immune response is the first line of defence against invading pathogens. We are devoted to understand the complex interplay between host defence and pathogen evasion. Our studies include the role of CD5L in modulating macrophage responses to bacterial products, from inflammatory molecules (eg LPS) to whole organisms, such as Escherichia coli or Mycobacterium tuberculosis. This line of research opens the door to the discovery of new therapeutic targets.

This work has been funded by ISCIII-ERDF (FIS IP10/1656, and Miguel Servet CP08/124).


Ongoing Projects

Novel cancer immunotherapy strategy and companion diagnostic
Code: 2019PROD00118
Principal Investigator Maria-Rosa Sarrias

More information

Start Date: 01/01/2017
End Date: 21/07/2020

Perfil fenotípico-funcional del macrófago en cirrosis y cáncer hepatocelular y su manifestación en plasma: nueva oportunidad pronóstico-terapéutica
Code: PI16/00974
Principal Investigator Maria-Rosa Sarrias

Start Date: 01/01/2017
End Date: 31/12/2019

New in Vitro Diagnostic devices for the clinical management of tuberculosis and hepatocellular carcinoma
Code: 2016 PRODUCTE 0094
Principal Investigator Maria-Rosa Sarrias

Start Date: 01/08/2017
End Date: 31/01/2019

Grup de recerca translacional en patologia hepàtica i immunitat innata
Code: 2017-SGR 490
Principal Investigator Carolina Armengol

Start Date: 01/01/2017
End Date: 31/12/2019

Children's Liver Tumour European Research Network
Code Grant Agreement: 668596
Principal Investigator K Wheatley (WP3 Leader: C Armengol, IGTP)

Start Date: 01/01/2016
End Date: 31/12/202


- Research

New immunotherapy targeting tumour macrophages to tackle lung cancer

Researchers from the Innate Immunity group at the Germans Trias i Pujol Research Institute (IGTP) have developed a new immunotherapy based on a monoclonal antibody directed against tumour macrophages. The results obtained lay the foundations for a new treatment for patients with lung cancer, with the potential to be applied to other solid tumours. The study has been published in the journal eBioMedicine.

- Research

A project that develops a new immunotherapy based on a monoclonal antibody to treat cancer is one of the three initiatives chosen by CaixaResearch Consolidate

A project that develops a monoclonal antibody for cancer treatment, led by the Innate Immunity Research Group at the IGTP, is one of the three selected in the CaixaResearch Consolidate call of “la Caixa” Foundation to cutting-edge innovative biomedical projects.

+ News


Maria-Rosa Sarrias, Group Leader

(+34) 93 554 3060